Adjuvant and ablative therapies for low-risk UTUC: avenues to enhance kidney preservation
Crossref DOI link: https://doi.org/10.1038/s41585-020-0338-4
Published Online: 2020-05-19
Published Print: 2020-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Raman, Jay D.
Text and Data Mining valid from 2020-05-19
Version of Record valid from 2020-05-19
Article History
First Online: 19 May 2020
Competing interests
: J.D.R. declares that he is a study site investigator for the OLYMPUS trial (NCT02793128) and a member of the strategic advisory board for Urogen Pharma Ltd.